Prospective study on nonalcoholic fatty liver disease treated with silibinin combined with Kezhi capsules

Abstract

Objective To investigate the curative effect of silibinin combined with Kezhi capsules in the treatment of patients with nonalcoholic fatty liver disease. Methods A total of 137 patients with nonalcoholic fatty liver disease in our hospital from January 2015 to June 2017 were divided into two groups according to different treatment methods. 68 cases in the control group were treated with silibinin, and 69 cases in the study group were treated with Kezhi capsules on the basis of the control group. The effect and the incidence of adverse reactions of the two groups were statistically recorded. The levels of serum liver function indexes [alanine aminotransferase (ALT), total bilirubin (TBIL), albumin (ALB), aspartate aminotransferase (AST)] and blood lipid indexes [total cholesterol (TC), triglyceride (TG), and low density lipoprotein (LDL-C)] of the two groups were measured. The quality of life (WHOQOL-100) scores were compared between the 2 groups before and after 3 months of treatment. Results The effect of the study group was better than that of the control group, and the total effective rate of the study group was 98.55% (68/69), higher than that of the control group [83.82% (57/68)] (P 0.05). After 3 months of treatment, the score of WHOQOL-100 in the study group [(89.61±8.24)points] was higher than that in the control group [(80.52±7.86)points] (t=6.605, P=0.000). Conclusion The combination of silibinin and Kezhi capsules is effective in the treatment of nonalcoholic fatty liver disease, which can effectively improve the liver function and blood lipid level, and improve the quality of life, with high safety. Key words: Kezhi capsule; Silibinin; Nonalcoholic fatty liver disease; Alanine aminotransferase; Total bilirubin